The Acute Respiratory Distress Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Respiratory Distress Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued products.
GlobalData tracks 123 drugs in development for Acute Respiratory Distress Syndrome by 114 companies/universities/institutes. The top development phase for Acute Respiratory Distress Syndrome is preclinical with 66 drugs in that stage. The Acute Respiratory Distress Syndrome pipeline has 119 drugs in development by companies and four by universities/ institutes. Some of the companies in the Acute Respiratory Distress Syndrome pipeline products market are: Pantherna Therapeutics, BioStem Technologies and Aqualung Therapeutics.
The key targets in the Acute Respiratory Distress Syndrome pipeline products market include Complement C5, C-X-C Chemokine Receptor Type 4, and Angiopoietin 1 Receptor.
The key mechanisms of action in the Acute Respiratory Distress Syndrome pipeline product include Complement C5 Inhibitor with two drugs in Phase II. The Acute Respiratory Distress Syndrome pipeline products include 14 routes of administration with the top ROA being Intravenous and 18 key molecule types in the Acute Respiratory Distress Syndrome pipeline products market including Small Molecule, and Cell Therapy.
Acute Respiratory Distress Syndrome overview
Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia, and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure, confusion, and extreme tiredness.
For a complete picture of Acute Respiratory Distress Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
